Dacarbazine in Veterinary Oncology: Infusion and Gastrointestinal-Risk Profile

dacarbazine is covered as triazene antineoplastic agents; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Triazene antineoplastic agents; hazardous antineoplastic medicine. Dacarbazine.

Dacarbazine.

Dacarbazine requires hepatic activation and generates methylating metabolites that damage DNA. It is generally classed as a nonclassical alkylating triazene.

Veterinary references describe selected lymphoma, sarcoma and melanoma contexts, often as part of combinations. It is not interchangeable with temozolomide merely because the drugs are related.

Veterinary references describe selected lymphoma, sarcoma and melanoma contexts, often as part of combinations. It is not interchangeable with temozolomide merely because the drugs are related.

Intravenous infusion in a chemotherapy-capable veterinary clinic

The veterinary evidence base is limited and tumour-specific. Protocol composition, prior treatment and formulation affect interpretation, so a historical response in one cohort cannot predict an individual animal’s result.

Severe acute nausea, vomiting and diarrhoea, phlebitis, marrow suppression and liver injury are recognised. Anecdotal pleural effusion has been described in cats, reinforcing the need for species-specific caution.

Other emetogenic, marrow-suppressive or hepatotoxic medicines can increase risk. Venous access and anti-nausea planning belong to the clinic.

No FDA-approved canine or feline oncology indication was established for this medicine in this audit. In the United States, veterinary oncology use of an approved human or animal formulation is extra-label and must occur under a veterinarian within AMDUCA conditions and a valid VCPR.

Multi-region specialist use; product availability, extra-label prescribing law and pharmacy handling vary by jurisdiction.

Baseline blood count and organ-function testing, secure venous access and an emesis plan are typical discussion points. The team selects post-treatment blood-count timing and evaluates fever, persistent gastrointestinal signs, infusion-site pain or respiratory change promptly.